Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- Not reported
- Expenses
- $840,000.00
- Registrant
- ALKERMES, INC.
- Client
- ALKERMES, INC.
- Filing UUID
- 5fefbe15-1e21-4453-81f4-89c85bc42b0f
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Literal federal measure citations: H.R. 2163, S. 464, H.R.1, H.R.1414, H.R.946
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Literal federal measure citations: H.R. 4030
Policies impacting pharmaceutical distribution and manufacturing
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.